Cover Image
市場調查報告書

中風:開發平台分析

Stroke - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 229744
出版日期 內容資訊 英文 593 Pages
訂單完成後即時交付
價格
Back to Top
中風:開發平台分析 Stroke - Pipeline Review, H1 2016
出版日期: 2016年05月25日 內容資訊: 英文 593 Pages
簡介

所謂中風是因為缺氧導致腦細胞死亡的症狀。症狀是會突然發生,並在短時間(通常數分到數小時)結束。最初患者會感到身體不適,臉色蒼白、精神非常差。還有可能產生突然性頭痛,或是突然臉部或手腳,尤其是身體一邊麻痺。口齒不清,或無法理解別人說話的內容、視力下降、走路難以保持平衡等症狀。甚至也會因癲癇發作而產生窒息。

本報告提供全球各國治療中風所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

中風概要

治療藥的開發

  • 中風開發中產品:概要
  • 中風開發中產品:比較分析

各企業開發中的中風治療藥

大學/研究機關研究中的中風治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 不明確的階段有的產品

中風治療藥:開發中的產品一覽(各企業)

中風治療藥:研究中的產品一覽(各大學/研究機關)

中風治療藥的開發企業

  • AB Science SA
  • Acorda Therapeutics, Inc.
  • Acticor Biotech
  • ActiveSite Pharmaceuticals, Inc.
  • Addex Therapeutics Ltd
  • advanceCor GmbH
  • Affibody AB
  • Amarantus Bioscience Holdings, Inc.
  • Anavex Life Sciences Corp.
  • Angion Biomedica Corp.
  • Antoxis Limited
  • Aralez Pharmaceuticals Inc.
  • ArmaGen Inc.
  • Asterias Biotherapeutics, Inc.
  • AstraZeneca Plc
  • Athersys, Inc.
  • Bayer AG
  • Bioasis Technologies Inc.
  • Biogen, Inc.
  • BioTime, Inc.
  • Cardax Pharmaceuticals, Inc.
  • Cellular Biomedicine Group, Inc.
  • CHA Bio & Diostech Co., Ltd.其他

中風:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

中風治療藥:開發中產品的最新趨勢

中風治療藥:暫停開發的產品

中風治療藥:中止開發的產品

中風相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7975IDB

Summary

Global Markets Direct's, 'Stroke - Pipeline Review, H1 2016', provides an overview of the Stroke pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Stroke and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Stroke
  • The report reviews pipeline therapeutics for Stroke by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Stroke therapeutics and enlists all their major and minor projects
  • The report assesses Stroke therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Stroke

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Stroke
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Stroke pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Stroke Overview
  • Therapeutics Development
  • Stroke - Therapeutics under Development by Companies
  • Stroke - Therapeutics under Investigation by Universities/Institutes
  • Stroke - Pipeline Products Glance
  • Stroke - Products under Development by Companies
  • Stroke - Products under Investigation by Universities/Institutes
  • Stroke - Companies Involved in Therapeutics Development
  • Stroke - Therapeutics Assessment
  • Drug Profiles
  • Stroke - Recent Pipeline Updates
  • Stroke - Dormant Projects
  • Stroke - Discontinued Products
  • Stroke - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Stroke, H1 2016
  • Number of Products under Development for Stroke - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Stroke - Pipeline by AB Science SA, H1 2016
  • Stroke - Pipeline by Acorda Therapeutics, Inc., H1 2016
  • Stroke - Pipeline by Acticor Biotech, H1 2016
  • Stroke - Pipeline by ActiveSite Pharmaceuticals, Inc., H1 2016
  • Stroke - Pipeline by Addex Therapeutics Ltd, H1 2016
  • Stroke - Pipeline by advanceCor GmbH, H1 2016
  • Stroke - Pipeline by Affibody AB, H1 2016
  • Stroke - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016
  • Stroke - Pipeline by Anavex Life Sciences Corp., H1 2016
  • Stroke - Pipeline by Angion Biomedica Corp., H1 2016
  • Stroke - Pipeline by Antoxis Limited, H1 2016
  • Stroke - Pipeline by Aralez Pharmaceuticals Inc., H1 2016
  • Stroke - Pipeline by ArmaGen Inc., H1 2016
  • Stroke - Pipeline by Asterias Biotherapeutics, Inc., H1 2016
  • Stroke - Pipeline by AstraZeneca Plc, H1 2016
  • Stroke - Pipeline by Athersys, Inc., H1 2016
  • Stroke - Pipeline by Bayer AG, H1 2016
  • Stroke - Pipeline by Bioasis Technologies Inc., H1 2016
  • Stroke - Pipeline by Biogen, Inc., H1 2016
  • Stroke - Pipeline by BioTime, Inc., H1 2016
  • Stroke - Pipeline by Cardax Pharmaceuticals, Inc., H1 2016
  • Stroke - Pipeline by Cellular Biomedicine Group, Inc., H1 2016
  • Stroke - Pipeline by CHA Bio & Diostech Co., Ltd., H1 2016
  • Stroke - Pipeline by D-Pharm Ltd., H1 2016
  • Stroke - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Stroke - Pipeline by DiaMedica Inc., H1 2016
  • Stroke - Pipeline by Digna Biotech, S.L., H1 2016
  • Stroke - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Stroke - Pipeline by Fina Biotech, H1 2016
  • Stroke - Pipeline by Genervon Biopharmaceuticals, LLC, H1 2016
  • Stroke - Pipeline by Glialogix, Inc., H1 2016
  • Stroke - Pipeline by Glucox Biotech AB, H1 2016
  • Stroke - Pipeline by Green Cross Corporation, H1 2016
  • Stroke - Pipeline by Grifols, S.A., H1 2016
  • Stroke - Pipeline by Huons Co., Ltd., H1 2016
  • Stroke - Pipeline by International Stem Cell Corporation, H1 2016
  • Stroke - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016
  • Stroke - Pipeline by JN-International Medical Corporation, H1 2016
  • Stroke - Pipeline by Laboratoires Pierre Fabre SA, H1 2016
  • Stroke - Pipeline by LegoChem Biosciences, Inc, H1 2016
  • Stroke - Pipeline by Living Cell Technologies Limited, H1 2016
  • Stroke - Pipeline by Lumosa Therapeutics Co., Ltd., H1 2016
  • Stroke - Pipeline by M et P Pharma AG, H1 2016
  • Stroke - Pipeline by Mapreg S.A.S., H1 2016
  • Stroke - Pipeline by Mast Therapeutics, Inc., H1 2016
  • Stroke - Pipeline by Medestea Research & Production S.p.A., H1 2016
  • Stroke - Pipeline by Mitochon Pharmaceuticals, Inc., H1 2016
  • Stroke - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016
  • Stroke - Pipeline by Neuralstem, Inc., H1 2016
  • Stroke - Pipeline by Neuren Pharmaceuticals Limited, H1 2016
  • Stroke - Pipeline by Neuronax SAS, H1 2016
  • Stroke - Pipeline by Neurotec Pharma SL, H1 2016
  • Stroke - Pipeline by NeuroVive Pharmaceutical AB, H1 2016
  • Stroke - Pipeline by New Haven Pharmaceuticals, Inc., H1 2016
  • Stroke - Pipeline by New World Laboratories, Inc., H1 2016
  • Stroke - Pipeline by NoNO, Inc., H1 2016
  • Stroke - Pipeline by Omeros Corporation, H1 2016
  • Stroke - Pipeline by Panacea Pharmaceuticals, Inc., H1 2016
  • Stroke - Pipeline by Pfizer Inc., H1 2016
  • Stroke - Pipeline by PharmatrophiX, Inc., H1 2016
  • Stroke - Pipeline by Pharmicell Co., Ltd., H1 2016
  • Stroke - Pipeline by Phoenix Biotechnology, Inc., H1 2016
  • Stroke - Pipeline by Phylogica Limited, H1 2016
  • Stroke - Pipeline by PhytoHealth Corporation, H1 2016
  • Stroke - Pipeline by Pluristem Therapeutics Inc., H1 2016
  • Stroke - Pipeline by Primary Peptides, Inc., H1 2016
  • Stroke - Pipeline by Q Therapeutics, Inc., H1 2016
  • Stroke - Pipeline by QR Pharma, Inc., H1 2016
  • Stroke - Pipeline by ReCyte Therapeutics, Inc., H1 2016
  • Stroke - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2016
  • Stroke - Pipeline by Remedy Pharmaceuticals, Inc., H1 2016
  • Stroke - Pipeline by ReNeuron Group Plc, H1 2016
  • Stroke - Pipeline by SanBio, Inc., H1 2016
  • Stroke - Pipeline by Saneron CCEL Therapeutics, Inc., H1 2016
  • Stroke - Pipeline by Simcere Pharmaceutical Group, H1 2016
  • Stroke - Pipeline by StemCells, Inc., H1 2016
  • Stroke - Pipeline by Stemedica Cell Technologies, Inc., H1 2016
  • Stroke - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016
  • Stroke - Pipeline by SynZyme Technologies, LLC, H1 2016
  • Stroke - Pipeline by Targazyme, Inc., H1 2016
  • Stroke - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016
  • Stroke - Pipeline by TikoMed AB, H1 2016
  • Stroke - Pipeline by vasopharm GmbH, H1 2016
  • Stroke - Pipeline by Vicore Pharma AB, H1 2016
  • Stroke - Pipeline by Virogenomics BioDevelopment, Inc., H1 2016
  • Stroke - Pipeline by WhanIn Pharmaceutical Co., Ltd., H1 2016
  • Stroke - Pipeline by Xigen SA, H1 2016
  • Stroke - Pipeline by Zocere, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Stroke Therapeutics - Recent Pipeline Updates, H1 2016
  • Stroke - Dormant Projects, H1 2016
  • Stroke - Dormant Projects (Contd..1), H1 2016
  • Stroke - Dormant Projects (Contd..2), H1 2016
  • Stroke - Dormant Projects (Contd..3), H1 2016
  • Stroke - Dormant Projects (Contd..4), H1 2016
  • Stroke - Dormant Projects (Contd..5), H1 2016
  • Stroke - Dormant Projects (Contd..6), H1 2016
  • Stroke - Dormant Projects (Contd..7), H1 2016
  • Stroke - Dormant Projects (Contd..8), H1 2016
  • Stroke - Dormant Projects (Contd..9), H1 2016
  • Stroke - Dormant Projects (Contd..10), H1 2016
  • Stroke - Dormant Projects (Contd..11), H1 2016
  • Stroke - Dormant Projects (Contd..12), H1 2016
  • Stroke - Dormant Projects (Contd..13), H1 2016
  • Stroke - Dormant Projects (Contd..14), H1 2016
  • Stroke - Discontinued Products, H1 2016
  • Stroke - Discontinued Products (Contd..1), H1 2016
  • Stroke - Discontinued Products (Contd..2), H1 2016
  • Stroke - Discontinued Products (Contd..3), H1 2016

List of Figures

  • Number of Products under Development for Stroke, H1 2016
  • Number of Products under Development for Stroke - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top